1. Introduction {#sec1}
===============

Head and neck soft tissue sarcomas (HNSTS) are a rare and heterogeneous group of malignancies accounting for approximately 1% of all head and neck malignancies. HNSTS represents 10% of all soft tissue sarcomas \[[@B1]\]. More than 80 histological subtypes are distinguished in the 2013 WHO classification \[[@B2]\]. Because of this rarity and the diverse clinical behaviours, management of HNSTS can be challenging and should be carried out in a multidisciplinary centre with expertise and experience in sarcomas \[[@B3]\].

Surgery remains to be the primary treatment choice, even though it is difficult to achieve free surgical margins due to the anatomy of the head and neck region \[[@B4]\]. When combined with surgery, radiotherapy may improve overall prognosis for some HNSTS depending on the histological type, whereas a better outcome is achieved for some histological subtypes when surgery is combined with chemotherapy, e.g., angiosarcoma, rhabdomyosarcoma, and synovial sarcoma \[[@B3], [@B5], [@B6]\].

The purpose of this study was to systematically review the literature on adult patients diagnosed with HNSTS and report the distribution of histological subtypes, treatment, and overall survival (OS) rates.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy and Eligibility Criteria {#sec2.1}
---------------------------------------------

The electronic databases PubMed and Embase were used for searching. The search strategy in PubMed included the following keywords: "Head and Neck," "Oral Cavity," "Pharynx," and "Sarcoma." The search strategy in Embase included the keywords "Head and Neck Sarcomas." Studies published from 2000 until March 2018 reporting patient databases of soft tissue sarcomas in the head and neck region with a minimum of 20 patients (\>18 years of age at diagnosis) were included. Studies reporting both localized disease and metastatic disease were included. Exclusion criteria were radiation-induced sarcomas, bone sarcomas, and studies that solely reported specific histological subtypes. Due to an update in WHO classification of soft tissue tumours in 1994, studies reporting patient cases from before 1994 were excluded.

2.2. Data Extraction {#sec2.2}
--------------------

We extracted data on country, number of cases, period, gender, age, histological subtypes, tumour size, and grading according to the French Federation of Cancer Centres Sarcoma Group (grade I, grade II, grade III, and unknown). Furthermore, *T* stage (0, 1, 2, 3, and 4), treatment (surgery, radiotherapy, and/or chemotherapy), surgical margins (R0, R1, R2, and unspecified/unknown), median follow up, 5-year OS, and 5-year disease-free survival (DFS) were also extracted. We applied the model of random effects to perform a meta-analysis of 5-year OS and 5-year DFS. Data analysis was performed in Stata, and a *p* value \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

We identified 2,056 publications, of which eight studies (1,120 cases; 66% males) from six different countries met the inclusion criteria. All studies reported the median age, which ranged from 35 to 68.5 years. In four studies (*n* = 897), 73% of the patients were more than 50 years of age ([Table 1](#tab1){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}).

Sarcomas with unidentified histology (*n* = 215) and uncommon sarcoma subtypes (*n* = 141) constituted one-third of the cohort (*n* = 1,083) being the most frequent histological subtypes. These were followed by fibrosarcomas/fibromatous sarcomas (*n* = 136), vascular sarcomas (*n* = 125), and leiomyosarcomas (*n* = 89). Noteworthy, in some of the included studies, the group "uncommon sarcomas" consisted of several sarcoma subtypes traditionally perceived as common sarcomas (e.g., rhabdomyosarcomas) ([Table 2](#tab2){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}). This was mainly seen in studies including a small number of cases. Hence, several of the cases classified as "uncommon sarcomas" could potentially be reclassified within one of the specified subtypes.

In seven studies (*n* = 1,090), the median follow-up period ranged from 23.8 to 72 months. Five-year OS was reported in five studies, 5-year DFS was reported in three studies, and their values were 74% (95% CI; 0.63--0.84%) and 56 % (95% CI; 38--74%), respectively ([Table 1](#tab1){ref-type="table"} and Figures [3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}).

Six studies (*n* = 1,060) reported tumour size as a binary outcome (\<5 cm or \>5 cm), two studies reported median tumour size, and one study reported both mean tumour size and tumour size as a binary outcome. In 57% of the cases, the tumour diameter was \<5 cm in diameter at the time of diagnosis. Mean tumour size ranged from 2.7 to 4.8 cm (*n* = 55). Tumour grading was stated in all studies included (*n* = 1,120). 84% of the tumours were grade III, 7% were grade II, 5% were grade I, and 3% were unspecified or unknown grade. The surgical resection margins were stated in seven studies (*n* = 1,092). 60% of the tumours had clear surgical margins (R0), 13% had microscopic involved margins (R1), 18% had macroscopic involved margins (R2), and 1% had unknown margins ([Table 1](#tab1){ref-type="table"}).

All studies (*n* = 1,120) reported treatment strategy ([Table 3](#tab3){ref-type="table"}).

4. Discussion {#sec4}
=============

To our knowledge, this is the first systematic review and meta-analysis to explore patient and tumour characteristics including OS, DFS, and treatment strategies for patients with a HNSTS. In the meta-analysis, the pooled results showed a 5-year OS of approximately 75% and a 5-year DFS of nearly 50%.

Surgery remains the cornerstone of treatment of HNSTS, but the close relation to vital anatomic structures complicates this treatment strategy, explaining the relatively low 5-year DFS. Several factors influence the degree of surgical resection, e.g., tumour location and size, the extend of invasion, and the performance status of the patient \[[@B14]\]. Even though surgery with wide resection margins remains a difficult task, this review shows that 90% of the patients were treated with surgery (± radiation therapy and/or chemotherapy), and wide surgical margins were obtained in 60% of the cases.

In the present study, 53% of the patients were treated with radiation therapy with or without surgery. Studies in patients with truncal or extremity soft tissue sarcomas have demonstrated an improved local control following adjuvant radiation therapy in patients with large grade II and grade III sarcomas. Furthermore, retrospective studies have shown an approximately 10% improvement in OS following adjuvant radiation therapy in patients with grade III sarcomas \[[@B15]\]. Similarly, radiation therapy has also been found to improve OS in HNSTS \[[@B7]\].

In order to improve 5-year DFS and 5-year OS, the value of neoadjuvant chemotherapy in high-graded truncal or extremity soft tissue sarcomas has been investigated. However, the study was closed prematurely because superiority for neoadjuvant treatment was not to be expected \[[@B16]\]. Nevertheless, neoadjuvant chemotherapy still holds a potential improvement in the prognosis of HNSTS, and prospective, multicentre studies are needed in order to gain information about the effect of neoadjuvant treatment including chemotherapy and radiation therapy. Furthermore, in a study by Blay et al., early evaluation by a multidisciplinary team demonstrated a significant improvement in relapse-free survival \[[@B17]\]. Hence, HNSTS should only be managed by a specialist multidisciplinary environment in order to ensure a uniform treatment protocol \[[@B18]\].

More than 80 histological subtypes of HNSTS have been identified \[[@B2]\]. In order to predict risk of metastasis and relapse, it is important to identify the exact histological classification. In this systematic review, 215 sarcomas could not be classified, and additional 141 sarcomas were classified as "uncommon sarcomas." It is remarkable that one-third of the cohort constituted of sarcomas with unknown histology and uncommon sarcoma subtypes. Noteworthy, the classification of soft tissue sarcomas has evolved considerably during the past decades, especially due to evolvement in immunohistochemical and genetic/molecular methods \[[@B19]\]. It is likely that a large number of the cases included in the present review would be reclassified if classified today. Furthermore, many of the cases where a specific pathological classification could not be obtained could probably be classified using modern methods. This may complicate applying the results of the present review on newly diagnosed patients with HNSTS. A high expertise in histological classification is crucial if more knowledge about behaviour and treatment of sarcomas must be achieved. It emphasizes the need of histological reevaluation of a special trained pathologist in the highest national level before treating and before publishing data of sarcomas.

The present systematic review and meta-analysis hold important limitations. Inclusion and exclusion criteria as well as staging and treatment varied between the included studies, which complicates interpretation. The included studies reported a few cases of sarcomas, which were not classified as soft tissue sarcomas; however, these constituted only a small part (1.3%) of the total cases included. The included studies originated from six countries, and the majority of the cases were obtained from a single study. All studies were retrospective, and the cases were obtained during long follow-up periods.

5. Conclusions {#sec5}
==============

HNSTS is a rare and heterogeneous tumour group with great differences in OS and DFS. The pooled results showed a 5-year OS of approximately 75% and a 5-year DFS of nearly 50%. However, studies show varying prognoses demonstrating the difficulty in treating HNSTS underlining the importance of uniformed treatment guidelines in order to achieve improved survival outcomes.

CG was funded by the nonprofit organization Candys Foundation and Kræftfonden (the Cancer Foundation).

Conflicts of Interest
=====================

The authors declare that there are no conflicts of interest regarding the publication of this article.

Authors\' Contributions
=======================

Sakshi Andersen and Henriette Mann contributed equally to this work.

![PRISMA 2009 flow diagram.](SARCOMA2019-9725637.001){#fig1}

![Histological subtypes.](SARCOMA2019-9725637.002){#fig2}

![5-year overall survival.](SARCOMA2019-9725637.003){#fig3}

![5-year disease-free survival.](SARCOMA2019-9725637.004){#fig4}

###### 

Patient data and characteristics.

                              Mahmoud et al. \[[@B7]\]   Andrä et al. \[[@B8]\]   González-González et al. \[[@B9]\]   Vitzthum et al. \[[@B10]\]   Tejani et al. \[[@B6]\]   Penel et al. \[[@B11]\]   Sidappa and Krishnamurthy \[[@B12]\]   Park et al. \[[@B13]\]   Total                                                          
  --------------------------- -------------------------- ------------------------ ------------------------------------ ---------------------------- ------------------------- ------------------------- -------------------------------------- ------------------------ ------- ---- ------ ------- ----- ------- ----- ------- ------ ----
  Country                     USA                        Germany                  Mexico                               USA                          USA                       France                    India                                  Korea                    *N*     \%                                                     
  Years                       2004--2013                 2003--2012               2004--2009                           1998--2012                   1999--2009                1997--2002                1996--2005                             1995--2012                                                                              
                              *N*                        \%                       *N*                                  \%                           *N*                       \%                        *N*                                    \%                       *N*     \%   *N*    \%      *N*   \%      *N*   \%              
  Cases                       788                                                 26                                                                51                                                  48                                                              30           28             27            122           1120    
  Male                        539                        68                       18                                   69                           31                        61                        34                                     71                       20      67   15     54      17    63      65    53      739    66
  Median age                  63                                                  64                                                                43.1                                                68.5                                                            50           45.7           35            46            ---     
   \<50                       181                        23^a^                    ---                                                               34                        67                        ---                                                             12      40   11     39      ---           ---           238    27
   \>50                       607                        77                       ---                                                               17                        33^b^                     ---                                                             18      60   17     61^b^   ---           ---           659    73
  Tumour size                                                                                                                                                                                                                                                                                                                           
   \<5 cm                     443                        56                       ---                                                               15                        29^c^                     33                                     69^c^                    13      43   ---            17    63      86    70^c^   607    57
   \>5 cm                     345                        44^d^                    ---                                                               36                        71                        15                                     31                       11      37   ---            10    37      36    30      453    43
  Mean tumour size (cm)       4.5^e^                                              4.6^e^                                                            ---                                                 ---                                                             ---          2.7            4.8                         ---     
  Grade (FNCLCC)                                                                                                                                                                                                                                                                                                                        
   High/G3                    788                        100                      17                                   65                           30                        59                        28                                     58^f^                    23      77   16     57      21    78^g^   22    18      945    84
   Intermediate/G2            0                                                   8                                    31                           10                        20                        0                                                               3       10   8      29      0             53    43      82     7
   Low/G1                     0                                                   1                                    4                            11                        22                        6                                      13                       2       7    2      7       6     22      30    25      58     5
   Unspecified/unknown        0                                                   0                                                                 0                                                   14                                     29                       2       7    2      7       0             17    14      35     3
  *T* stage                                                                                                                                                                                                                                                                                                                             
   0                          ---                                                 ---                                                               ---                                                 ---                                                             ---          ---            ---           ---           ---     
   1                          ---                                                 14                                   54                           13                        25                        ---                                                             12      40   ---            ---           ---           39     23
   2                          ---                                                 12                                   46                           38                        75                        ---                                                             18      60   ---            ---           ---           68     40
   3                          ---                                                 ---                                                               ---                                                 ---                                                             ---          ---            ---           ---           ---     
   4                          ---                                                 ---                                                               ---                                                 ---                                                             ---          ---            ---           ---           ---     
  Surgical margins^†^                                                                                                                                                                                                                                                                                                                   
   R0                         497                        63                       10                                   39                           35                        69                        41                                     85                       17      57   ---            20    74      76    62      696    60
   R1                         111                        14                       6                                    23                           4                         8                         ---                                                             7       23   ---            6     22^h^   20    16      154    13
   R2                         180                        23                       5                                    19                           13                        25                        3                                      6                        ---          ---            ---           7     6       208    18
   Unspecified/unknown        ---                                                 5                                    19                           ---                                                 4                                      8                        ---          ---            ---           ---           9      1
  5-year OS                   ---                                                                                      82                           ---                                                                                        83                               46   ---            68            75            ---     
  5-year DFS                  ---                                                 ---                                                               ---                                                                                        63                               35   ---            65            ---           ---     
  Median follow-up (months)   45                                                  39                                                                23.8                                                57.6                                                            ---          27             59            72            ---     

^a^≤50, ^b^≥50, ^c^≤5, ^d^≥5, ^e^median, ^f^grade 2 + 3, ^g^grading system not specified in the article, and ^h^R1 + R2. ^†^R0 = negative surgical margins/clear margins, R1 = microscopic positive surgical margins/microscopic involved margins, and R2 = macroscopic positive margins/macroscopic involved margins.

###### 

Histological subtypes.

                                        Mahmoud et al. \[[@B7]\]   Andrä et al. \[[@B8]\]   González-González et al. \[[@B9]\]^*∗*^   Vitzthum et al. \[[@B10]\]^*∗*^   Tejani et al.\[[@B6]\]   Penel et al. \[[@B11]\]^*∗*^   Sidappa and Krishnamurthy \[[@B12]\]   Park et al. \[[@B13]\]   Total
  ------------------------------------- -------------------------- ------------------------ ----------------------------------------- --------------------------------- ------------------------ ------------------------------ -------------------------------------- ------------------------ -------
  Alveolar soft part sarcoma            ---                        ---                      ---                                       ---                               1                        ---                            ---                                    3                        4
  Angiosarcoma                          ---                        9                        ---                                       14                                4                        5                              ---                                    15                       47
  Carcinosarcoma                        ---                        ---                      ---                                       ---                               1                        ---                            ---                                    ---                      1
  Chondrosarcoma                        ---                        ---                      ---                                       ---                               ---                      ---                            ---                                    8                        8
  DFSP^▪^                               ---                        ---                      ---                                       1                                 ---                      ---                                                                   16                       17
  Epithelioid sarcoma                   ---                        ---                      ---                                       ---                               1                        1                              ---                                    ---                      2
  Ewing\'s sarcoma/PNET^◊^              ---                        ---                      ---                                       ---                               ---                      ---                            ---                                    4                        4
  Fibrosarcoma/fibromatous sarcoma^○^   125                        ---                      ---                                       ---                               1                        2                              1                                      7                        136
  Histiocytic sarcoma                   ---                        ---                      ---                                       ---                               1                        ---                            ---                                    ---                      1
  Leiomyosarcoma                        76                         ---                      ---                                       5                                 3                        ---                            1                                      4                        89
  Lipomatous sarcoma^∆^                 31                         ---                      ---                                       3                                 4                        ---                            ---                                    10                       48
  Low-grade fibromyxoid sarcoma         ---                        ---                      ---                                       ---                               ---                      ---                            ---                                    2                        2
  MFH/undiff. pleo./UPS^∞^              ---                        5                        ---                                       9                                 ---                      2                              6                                      3                        25
  Neurofibromatous sarcoma^□^           46                         ---                      9                                         1                                 ---                      ---                            5                                      ---                      61
  Osteosarcoma                          ---                        ---                      ---                                       ---                               ---                      ---                            ---                                    5                        5
  Others^•^                             ---                        8                        ---                                       3                                 ---                      ---                            ---                                    5                        16
  Peripheral neuroectodermic tumour     ---                        ---                      ---                                       ---                               ---                      3                              ---                                    ---                      3
  Rhabdomyosarcoma                      ---                        ---                      7                                         1                                 5                        7                              ---                                    24                       44
  Spindle cell                          ---                        ---                      ---                                       4                                 3                        ---                            10                                     9                        26
  Synovial sarcoma                      34                         4                        ---                                       6                                 6                        2                              1                                      7                        60
  Uncommon sarcoma subtypes^†^          139                        ---                      ---                                       ---                               ---                      ---                            2                                      ---                      141
  Undifferentiated sarcoma              ---                        ---                      ---                                       ---                               ---                      3                              ---                                    ---                      3
  Unidentified sarcoma^♦^               215                        ---                      ---                                       ---                               ---                      ---                            ---                                    ---                      215
  Vascular sarcoma^‡^                   122                        ---                      ---                                       2                                 ---                      ---                            1                                      ---                      125

^*∗*^Not all of the histological subtypes were reported. ^▪^Dermatofibrosarcoma protuberans. ^◊^Primitive neuroectodermal tumour. ^○^Including fibrosarcoma NOS, fibromyxoma, and fibrous histiocytoma. ^∆^Including myxosarcoma, angiomyxoma, atypical lipoma, liposarcoma NOS, fibromyxolipoma, myxoid, round cell, pleomorphic, mixed, and dedifferentiated liposarcoma, and spindle cell lipoma. ^∞^MFH = malignant fibrous histiocytoma, undiff. pleo. = undifferentiated pleomorphic sarcoma. UPS = unclassified pleomorphic sarcoma. ^□^Including neurosarcoma and malignant peripheral nerve sheath tumour. ^•^Andrä et al. \[[@B8]\], not otherwise specified; Vitzthum et al. \[[@B10]\], dendritic cell sarcoma, chordoma, and hemangioengothelioma; Park et al. \[[@B13]\], folicular dendritic cell sarcoma and teratocarcinosarcoma. ^†^Including clear cell, dermatofibrosarcoma, rhabdomyosarcoma, epithelioid, desmoplastic small round cell tumour, fascial, infantile, angiomatoid, fibrous histiocytoma, rhabdoid, giant cell tumour of soft part, and alveolar soft part. ^♦^Sarcomatosis not otherwise specified (NOS), spindle cell, giant cell, small cell, and undifferentiated sarcoma. ^‡^Including hemangiosarcoma, malignant hemangioendothelioma, epithelioid hemangioendothelioma, malignant hemangiopericytoma, hemangiopericytoma, and lymphangiosarcoma.

###### 

Treatment.

                      Mahmoud et al. \[[@B7]\]   Andrä et al. \[[@B8]\]   González-González et al. \[[@B9]\]   Vitzthum et al. \[[@B10]\]   Tejani et al. \[[@B6]\]   Penel et al. \[[@B11]\]   Sidappa and Krishnamurthy \[[@B12]\]   Park et al. \[[@B13]\]   Total                                               
  ------------------- -------------------------- ------------------------ ------------------------------------ ---------------------------- ------------------------- ------------------------- -------------------------------------- ------------------------ ------- ---- ---- ---- ---- ----- ----- ---- ------ ----
  Surgery             788                        100                      21                                   81                           48                        94                        30                                     63                       24      80   19   68   26   96    103   84   1059   90
  Radiation therapy   414                        53                       26                                   26                           33                        65                        34                                     71                       18      60   14   50   21   78    65    53   625    53
  Chemotherapy        126                        16                       13                                   13                           12                        24                        2                                      4                        10      33   8    29   0    ---   42    34   213    18

[^1]: Academic Editor: C. Verhoef
